Comparative UV Spectroscopic Method Analysis and Validation for Estimation of Rifaximin in Pharmaceutical Preparation
In the present research work the absorption characteristics of rifaximin was studied and validated in different solvents in visible region for its quantitative estimation in bulk and dosage forms by UV spectrophotometric method. The solution of Rifaximin were prepared in 0.1N HCL (pH 1.2), Phosphate buffer (pH 6.8) & Phosphate buffer (pH 7.4) and showed maximum absorption at wavelength 439 nm, 440 nm & 433 nm in respective solvents. The drug obeyed Beer–Lambert’s law in the concentration range of 2, 4, 6, 8, 10 µg/mL with coefficient of correlation (r2) of 0.998. The estimation method was validated as per the ICH guidelines. Statistical analysis proved that the methods are repeatable and specific for the estimation of the said drug. These methods can be adopted in routine analysis of Rifaximin in bulk or tablet dosage form.
Keywords: Rifaximin, 0.1N HCL, phosphate buffer, UV spectrophotometer.
2. Rivkin A., Gim S. Rifaximin: new therapeutic indication and future directions. Clinical Therapeutics. 2011; 33(7):812-827. https://doi.org/10.1016/j.clinthera.2011.06.007 PMid:21741091
3. Sudha T., Anandakumar K., Hemalatha P. V., Ravikumar V. R., Radhakrishnan Spectrophotometric estimation methods for Rifaximin in tablet dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2010; 2(1):43-46.
4. Mullen K. D., Sanyal A. J., Bass N. M., et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clinical Gastroenterology and Hepatology. 2014; 12(8):1390-1397. https://doi.org/10.1016/j.cgh.2013.12.021 PMid:24365449
5. Yoshida, T. Bioorg & Med Chem., 2012; 20:5705-5719.
6. Scott, A.I., Interpretation of Ultraviolet Spectra of Natural Products, Pergamon Press, New York, 1964.
7. Skoog, D.A. Holler, F.J., Nieman, D.A., Introduction to UV Spectroscopy in, principle of instrumental analysis, 5thed., Cole publication, 2004.
8. Chatwal G. R, Anand S. K, "Instrumental Methods of Chemical Analysis", 5 th Edn., Himalaya Publishing House, New Delhi, 2002; 566-587, 624-639. 3. Beckett. A. H., Stenlake J. B. Practical Pharmaceutical chemistry CBS Publishers and distributors, New Delhi., 1997, Ultraviolet visible absorption spectrophotometric. 2002; 275-278.
9. Rivkin A., Gim S. Rifaximin: new therapeutic indication and future directions. ClinicalTherapeutics. 2011; 33(7):812-827. https://doi.org/10.1016/j.clinthera.2011.06.007 PMid:21741091
10. International Conference on Harmonization. ICH. (2005). ICH - Q2 (R1): Guideline on Validation of Analytical Procedure: Text and Methodology.
11. International Conference on Harmonization, ICH (2003). Q2 (R1): Validation of analytical procedures: test and methodology.
12. Martindale. The Extra Pharmacopoeia. Published by direction of the Council of Royal Pharmaceutical Society of Great Britain. 34th ed, Vol. 11. London Royal Pharmaceutical Society, 2005; 653-656
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).